Oncoral

About Ascelia Pharma

Ascelia Pharma is a publicly traded biotech company dedicated to improving the lives of people with rare oncology-related conditions by identifying, developing, and commercializing novel drugs. The company's most advanced asset, Orviglance, has successfully completed a pivotal Phase 3 study and its New Drug Application (NDA) has been accepted for review by the FDA, representing a significant regulatory milestone. With a second candidate, Oncoral, advancing in clinical development and a clear focus on orphan oncology, Ascelia aims to address significant unmet medical needs in areas like liver metastases and gastric cancer.

Therapeutic Areas